Thursday - April 10, 2025
Johnson & Johnson Statement on VENTURA Program
March 07, 2025
NEW BRUNSWICK, New Jersey, March 7 -- Johnson and Johnson issued the following news release:

* * *

Johnson & Johnson Statement on VENTURA Program

TITUSVILLE, N.J., March 6, 2025 - Johnson & Johnson has made the decision to discontinue the Phase 3 VENTURA development program evaluating aticaprant as an adjunctive treatment for major depressive disorder (aMDD) due to insufficient efficacy in the target patient population. The data confirmed aticaprant . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products